

Donor leucocyte infusion

Adriana Martins de Sousa^{1*} , Rita de Cassia Barbosa Tavares² , Gil Cunha De Santis³ ,
Adriana Seber^{4,5} 

1. Universidade Federal do Rio de Janeiro  – Instituto de Puericultura e Pediatria Martagão Gesteira – Rio de Janeiro (RJ), Brazil.
2. Instituto Nacional do Câncer  – Centro de Transplante de Medula Óssea – Rio de Janeiro (RJ), Brazil.
3. Universidade de São Paulo  – Hospital das Clínicas de Ribeirão Preto – Hemocentro – Ribeirão Preto (SP), Brazil.
4. Hospital Samaritano de São Paulo  – São Paulo (SP), Brazil.
5. Grupo de Apoio ao Adolescente e à Criança com Câncer  – São Paulo (SP), Brazil.

*Corresponding author: adrisousa74@gmail.com

Section editor: Fernando Barroso Duarte 

Received: Sept. 24, 2025 • Accepted: Nov. 21, 2025

ABSTRACT

Donor-derived cellular therapies play a pivotal role in optimizing outcomes after allogeneic hematopoietic stem-cell transplantation (HCT). This article reviews three key post-transplant interventions: donor lymphocyte infusion (DLI), hematopoietic stem-cell boost, and mesenchymal stromal cell (MSC) infusion. DLI remains a cornerstone strategy for enhancing graft-versus-leukemia effects, preventing or treating relapse, and promoting immune reconstitution, while also carrying risk of graft-versus-host disease. Stem-cell boosts, typically performed using CD34⁺ selected products, offer an effective approach for managing poor graft function or mixed chimerism without significantly increasing alloimmune toxicity. MSC infusion has emerged as a promising immunomodulatory therapy for steroid-refractory graft-versus-host disease and for facilitating engraftment, owing to its anti-inflammatory and tissue-regenerative properties.

Keywords: Lymphocyte Transfusion. Graft vs Host Disease. Mesenchymal Stem Cells.

INTRODUCTION

Since the 1990s donor leucocyte infusion (DLI), has been used for the prevention and treatment of relapse after HCT, to the reversal of mixed chimerism particularly in non-malignant diseases after reduced-intensity conditioning, and as an adjuvant therapy for persistent viral infections^{1,2}.

Several strategies involving donor T cell manipulation have been developed to enhance the graft-versus-leukemia (GvL) effect while minimizing graft-versus-host disease (GvHD), such as activation of specific cell subsets with cytokines or growth factors, selection, and expansion of T cell subpopulations, infusion of NK cells, among others. Nevertheless, unmanipulated DLI, dosed based on the number of CD3⁺ T cells, remains the standard approach across centers^{3,4}.

FACTORS INFLUENCING DONOR LEUCOCYTE INFUSION RESPONSE

- Minimal residual disease (MRD) positivity and decreasing donor chimerism are risk factors for relapse^{1,5};

- Disease sensitivity to DLI: high in chronic myeloid leukemia (CML), myelofibrosis, and indolent non-Hodgkin lymphoma; intermediate in acute myeloid leukemia (AML), myelodysplastic syndrome, myeloma, and Hodgkin lymphoma; and low in acute lymphocytic leukemia and aggressive lymphomas¹;
- Donor-receptor human leukocyte antigen (HLA) disparities: inversely associated with required DLI dose¹;
- Graft source and manipulation: higher DLI doses are tolerated after bone marrow or *in-vivo* T-depleted graft (e.g., with antithymocyte globulin or alemtuzumab), whether for prophylactic, pre-emptive or therapeutic purposes¹;
- DLI schedule: escalating dose and intervals (Table 1);

Table 1. Donor leucocyte infusion schedule according to indication, timing, and donor type.

DLI	Timing for the first dose	MRD (CD3/kg)	MUD (CD3/kg)	MMUD/Haplo (CD3/kg)	Number of doses	Second to fourth doses	Interval between doses
Prophylactic <i>If there are no signs of GvHD</i>	Three months <i>If ex-vivo TCD and any risk</i>	$1 \times 10^5/\text{kg}$	$1 \times 10^5/\text{kg}$	$1 \times 10^5/\text{kg}$	1–3	0.5–1 log increase*	6–8 weeks
	Six months <i>If no ex-vivo TCD and HR disease</i>	$1 \times 10^6/\text{kg}$	$1 \times 10^6/\text{kg}$	$5 \times 10^5/\text{kg}$	1–3	0.5–1 log increase*	6–8 weeks
Pre-emptive <i>If there are no signs of GvHD</i>	Three months	$1–5 \times 10^5/\text{kg}$	$1 \times 10^5/\text{kg}$	$1 \times 10^5/\text{kg}$	1–4*	0.5–1 log *	4–6 weeks
	Six months	$1–3 \times 10^6/\text{kg}$	$1 \times 10^6/\text{kg}$	$1 \times 10^6/\text{kg}$	1–4*	0–5–1 log *	4–6 weeks
Therapeutic	After systemic therapy	$1 \times 10^7/\text{kg}$	$1 \times 10^7/\text{kg}$	$1 \times 10^6/\text{kg}$	1–4	Increase 1 log max $1 \times 10^8/\text{kg}$	4–6 weeks
G-DLI + CsA [‡] <i>If no GvHD</i>	D+21, D+35 and D+60	-	-	$1 \times 10^6/\text{kg}$	1	Increase 0.5 log if no GvHD	14 to 25 days
				$5 \times 10^6/\text{kg}$	2		

DLI: donor leucocyte infusion; MRD: minimal residual disease; MUD: matched unrelated donor; MMUD: mismatched unrelated donor; HAPLO: haploidentical; GvHD: graft-versus-host disease; TCD: T cell depletion; HR: risk disease; CsA: cyclosporine; *chimerism/MRD/GvHD guided; [‡]DLI granulocyte-stimulating factor (G-CSF)-mobilized, keeping cyclosporine until D+60 and then start tapering over four weeks¹⁷. Source: modified from Pagliuca S, 2024¹.

- Combination with specific targeted or immunomodulatory drugs (e.g., hypomethylating agents, tyrosine kinase inhibitors, blinatumomab, interferon, granulocyte-macrophage colony-stimulating factor): may enhance efficacy but require close monitoring for toxicity and dose adjustment¹;
- HLA loss by leukemic cells (in 10–30% of relapses after HLA-mismatched HCT): renders DLI ineffective and increases GvHD risk⁶. Molecular HLA typing is recommended before DLI¹.

SOURCE OF DONOR LEUCOCYTE INFUSION

- Conventional DLI: unstimulated apheresis. The first dose is usually given fresh, and subsequent aliquots are cryopreserved. It is worth noting that cryopreservation reduces lymphocyte effect¹;
- DLI collected after mobilization with granulocyte colony-stimulating factor (G-DLI), usually at the same time of stem cell collection. It may enhance the GvL activity without increasing the risk of GvHD⁷;
- Fresh whole blood DLI: collected in small aliquots from the donor's peripheral blood without apheresis, counted and infused⁸.

INDICATIONS FOR DONOR LEUCOCYTE INFUSION^{1,9–12}

Prophylactic donor leucocyte infusion

- After *ex-vivo* T-depletion grafts, to restore GvL effect and reduce relapse risk;
- Leukemias with very high-risk cytogenetic and molecular alterations;

- Diseases that have failed more than two lines of treatment;
- Positive MRD pre-HCT or disease status $\geq$ second complete remission;
- Second HCT, after immunosuppressor suspension (if GvHD is absent by D+60);
- Previous rituximab for Epstein Barr virus reactivation or post-transplant lymphoproliferative disease^{13–16};
- In general, it starts at least $\geq$ 90 days after HCT (accordingly disease *versus* GvHD risks);
- Early administration of G-DLI after HCT for high-risk leukemia^{17,18}.

Preemptive donor leucocyte infusion

- Mixed chimerism (for non-malignant or malignant diseases);
- Persistent or recurrent MRD;
- Clinical option in severe viral infections.

Therapeutic donor leucocyte infusion

- Hematological and/or extramedullary relapse.

PREREQUISITES FOR DONOR LEUCOCYTE INFUSION¹²

- Resolution of tissue damage and inflammatory conditions (severe infections or endothelitis);
- No systemic immunosuppressive medications for at least three to six weeks (may be longer in the setting of mismatched donor transplantation).

Exceptions:

- In high-risk disease, early DLI infusion may be considered even if the patients are still on immunosuppression;
- Therapeutic DLI may be offered earlier;
- Absence of active acute and chronic GvHD;
- No prior clinically significant GvHD;
- No graft rejection (loss of donor chimerism).

CLINICAL DATA SUPPORTING DONOR LEUCOCYTE INFUSION^{1,9,19,20–25}

- Pediatric AML patients show higher remission rates after first DLI compared to adults. Prophylactic DLI outperforms preemptive or therapeutic use, especially in AML and CML, with complete response rates up to 80% and five-year overall survival near 70%²¹;
- Prophylactic DLI plus azacitidine has been associated with two-year leukemia-free survival up to 88%, improved immune reconstitution, and no increase in GvHD^{22,23};
- Conversion from mixed to full donor chimerism is more frequent in leukemia than in non-malignant diseases, and more likely with matched sibling or haploidentical donors than unrelated donors;
- Early scheduling of prophylactic DLI rather than preemptive DLI in high-risk acute leukemia may reduce post-transplant relapse and improve long-term survival²⁴;
- In pediatric acute leukemia, DLI can successfully treat relapse, with remission rates ranging from 20 to 80%;
- It is worth noting that relapse rates are higher in Brazil than in higher income²⁵.

TOXICITIES

The most important complications of DLI are GvHD and pancytopenia. GvHD risk increases with early DLI post-HCT, higher cell doses ($> 1 \times 10^8$ T cells/kg), HLA mismatch, and lack of immunosuppression. Dose escalation every 4–12 weeks may reduce GvHD risk, especially in indolent disease or molecular relapse.

Aplasia is more common with mixed chimerism and may occur even with G-CSF–mobilized cells. Monitoring includes weekly clinical and laboratory assessments; if GvHD develops, perform severity score assessment, including lung function tests every three to six months, even in asymptomatic patients.

STEM CELL BOOST^{26–35}

Indications: Patients with poor graft function or declining donor chimerism after allogeneic HCT may benefit from a stem cell boost (SCB).

Limitations in Brazil: Although CD34⁺-selected products are commonly described in the international literature, this strategy remains highly restricted in Brazil. As a result, SCB is rarely used in Brazilian clinical practice.

- Administration and risks of boost without CD34⁺ selection: When SCB is used, it is typically performed with apheresis of G-CSF–mobilized peripheral blood stem cells. This unselected approach is associated with a higher CD3⁺ T cell content, which may increase the risk of acute GvHD, and its efficacy remains controversial. If performed, careful attention must be given to the CD3⁺ T cell dose infused, to minimize the risk of GvHD.
- Supportive measures: Other supportive strategies to improve graft function should also be considered, such as appropriate iron chelation and the use of agents like eltrombopag³¹.
- Cryopreserved autologous stem cells boost: Boost of previously cryopreserved autologous stem cells can be used to treat prolonged cytopenias after autologous HCT or after CAR-T cell therapy. In both settings, it is important to identify patients at highest risks, so a backup collection can be planned³⁵.

MESENCHYMAL STROMAL CELL^{36–43}

Definition and mechanisms

- Non-hematopoietic mesoderm-derived cells with regenerative and immunomodulatory properties;
- Sourced from bone marrow, adipose tissue, or umbilical cord;
- Inhibit T, B, NK, and monocyte activity, reducing inflammation and promoting immune tolerance^{37,38}.

Indications

- Used for tissue repair (*e.g.*, osteonecrosis) and treatment of immune-mediated complications³⁶;
- Mostly used for acute or chronic steroid-refractory GvHD post-HCT.

Evidence and administration

- Studies demonstrate safety and efficacy, especially in pediatrics^{40–42}, with approximately 50% of children achieving clinical response;
- Dosing: $2\text{--}4 \times 10^6$ mesenchymal cells (MSC)/kg twice weekly; source and protocol vary by center⁴²;
- European Society for Blood and Marrow Transplantation recommends MSC as second-line (category 2A) for acute GvHD³⁹;
- Food and Drug Administration approved Remestemcel-L in 2024 for steroid-refractory^aGvHD in children ≥ 2 months old⁴³.

LIMITATIONS IN BRAZIL

Not yet commercially approved; the Brazilian Health Regulatory Agency must be notified for use.

Post-transplant cellular therapies—including DLI, SCB, and MSC—offer important immunomodulatory and supportive strategies after HCT. While DLI is the most established, with proven benefit in relapse prevention, SCB may aid in graft function recovery, and MSC shows promise in steroid-refractory GvHD, especially in pediatrics.

However, all approaches face challenges such as limited availability, especially in Brazil, and lack of standardized protocols. Broader access to feasible options like fresh whole blood DLI, and further studies to define optimal indications, combinations, and emerging immune targets, are essential to improve outcomes in diverse transplant settings.

CONFLICT OF INTEREST

Nothing to declare.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable.

AUTHORS' CONTRIBUTIONS

Substantive scientific and intellectual contributions to the study: Sousa AM, Tavares RCB, Santis GC and Seber A. **Conception and design:** Sousa AM, Seber A and Tavares RCB. **Technical procedures:** Sousa AM and Seber A. **Manuscript writing:** Sousa AM, Tavares RCB, Santis GC and Seber A. **Final approval:** Sousa AM and Seber A.

FUNDING

Not applicable.

ACKNOWLEDGEMENTS

Not applicable.

REFERENCES

1. Pagliuca S, Schmid C, Santoro N, Simonetta F, Battipaglia G, Guillaume T, Greco R, Onida F, Sánchez-Ortega I, Yakoub-Agha I, Kuball J, Hazenberg MD, Ruggeri A; Practice Harmonization and Guidelines Committee and the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. *Lancet Haematol*. 2024;11(6):e448–58. [https://doi.org/10.1016/S2352-3026\(24\)00098-X](https://doi.org/10.1016/S2352-3026(24)00098-X)
2. Filicko-O'Hara J, Grosso D, Flomenberg PR, Friedman TM, Brunner J, Drobyski W, Ferber A, Kakhniashvili I, Keever-Taylor C, Mookerjee B, Talano JA, Wagner JI, Korngold R, Flomenberg N. Antiviral responses following L-leucyl-L-leucine methyl ester (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease. *Biol Blood Marrow Transplant*. 2009;15(12):1609–19. <https://doi.org/10.1016/j.bbmt.2009.08.020>
3. Ye Y, Yang L, Yuan X, Huang H, Luo Y. Optimization of donor lymphocyte infusion for aml relapse after allo-HCT in the era of new drugs and cell engineering. *Front Oncol*. 2021;11:790299. <https://doi.org/10.3389/fonc.2021.790299>

4. Greiner J, Götz M, Bunjes D, Hofmann S, Wais V. Immunological and clinical impact of manipulated and unmanipulated DLI after allogeneic stem cell transplantation of AML patients. *J Clin Med*. 2019;9(1):39. <https://doi.org/10.3390/jcm9010039>
5. Schmid C, Labopin M, Schaap N, Veelken H, Brecht A, Stadler M, Finke J, Baron F, Collin M, Bug G, Ljungman P, Blaise D, Tischer J, Bloor A, Kulagin A, Giebel S, Gorin NC, Esteve J, Ciceri F, Savani B, Nagler A, Mohty M. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. *Bone Marrow Transplant*. 2022;57(2):215–23. <https://doi.org/10.1038/s41409-021-01515-3>
6. Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, Perrelli NF, Cosentino C, Torri F, Angius A, Forno B, Casucci M, Bernardi M, Peccatori J, Corti C, Bondanza A, Ferrari M, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K. Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. *N Engl J Med*. 2009;361(5):478–88.
7. Lamure S, Paul F, Gagez AL, Delage J, Vincent L, Fegueur N, Sirvent A, Gehlkopf E, Veyrune JL, Yang LZ, Kanouni T, Cacheux V, Moreaux J, Bonafoux B, Cartron G, De Vos J, Ceballos P. A retrospective comparison of DLI and gDLI for post-transplant treatment. *J Clin Med*. 2020;9(7):2204. <https://doi.org/10.3390/jcm9072204>
8. Swaminathan VV, Uppuluri R, Patel S, Sivashankaran M, Ravichandran N, Ramanan KM, Ramakrishnan B, Vaidhyathan L, Raj R. Safety and efficacy of fresh whole blood donor lymphocyte infusion in children. *Bone Marrow Transplant*. 2019;54(11):1892–7. <https://doi.org/10.1038/s41409-019-0580-7>
9. Velázquez GF, Weller JF, Rubeck A, Arndt T, Schiele S, Mezger M, et al. Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukemia and myelodysplastic syndrome: validation of current recommendations and proposal of a modified outcome assessment. *Haematologica*. 2025;110(10):2293–304. <https://doi.org/10.3324/haematol.2024.287206>
10. Wu N, Yan CH, Kong J, Lv M, Mo XD, Sun YQ, Cheng YF, Xu LP, Zhang XH, Huang XJ, Wang Y. Prophylactic versus preemptive donor lymphocyte infusion in refractory/relapsed AML post-allogeneic transplant: a retrospective comparative study. *Transplant Cell Ther*. 2025:S2666-6367(25)01532-5. <https://doi.org/10.1016/j.jtct.2025.10.029>
11. Stadler M, Hambach L, Dammann E, Diedrich H, Kamal H, Hamwi I, Schultze-Florey C, Varvenne M, Ehrlich S, Buchholz S, Koenecke C, Beutel G, Weissinger EM, Krauter J, Eder M, Hertenstein B, Ganser A. The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease. *Ann Hematol*. 2023;102(9):2529–42. <https://doi.org/10.1007/s00277-023-05276-5>
12. Santoro N, Schmid C, de Witte M, Roeven MWH, Potter V, Richardson D, Schroeder T, Válková V, Clesham K, Loran S, Passweg J, Besley C, Gruhn B, Hoogenboom JD, Mooyaart JE, Sanchez-Ortega I, Pagliuca S, Simonetta F, Battipaglia G, Guillaume T, Hazenberg MD, Malard F, Kuball J, Ruggeri A. Current use of donor lymphocyte infusions after allogeneic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT. *Bone Marrow Transplant*. 2025;60(5):697–701. <https://doi.org/10.1038/s41409-025-02555-9>
13. De Jong G, Gillissen MA, Spits H, Hazenberg MD. Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation. *Immunooncol Technol*. 2020;7:15–22. <https://doi.org/10.1016/j.iotech.2020.07.002>
14. Gillissen MA, de Jong G, Levie SE, Yasuda E, Bakker AQ, Evers LM, Pals ST, Huisman C, van Helden PM, Spits H, Hazenberg MD. AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses. *Bone Marrow Transplant*. 2016;51(9):1245–8. <https://doi.org/10.1038/bmt.2016.90>

15. Marjańska A, Pogorzała M, Dziedzic M, Czyżewski K, Richert-Przygońska M, Dębski R, Bogiel T, Styczyński J. Impact of prophylaxis with rituximab on EBV-related complications after allogeneic hematopoietic cell transplantation in children. *Front Immunol*. 2024;15:1427637. <https://doi.org/10.3389/fimmu.2024.1427637>
16. Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh AA, Hashmi S, Ho A, Horowitz MM, Iida M, Jaimovich G, Karduss A, Kadera Y, Kröger N, Péffault de Latour R, Lee JW, Martínez-Rolón J, Pasquini MC, Passweg J, Paulson K, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Koh MBC, Aljurf M, Greinix H, Atsuta Y, Saber W. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. *Haematologica*. 2022;107(5):1045–53. <https://doi.org/10.3324/haematol.2021.279189>
17. Jaiswal SR, Zaman S, Chakrabarti A, Sen S, Mukherjee S, Bhargava S, Ray K, O'Donnell PV, Chakrabarti S. Improved outcome of refractory/relapsed acute myeloid leukemia after post-transplantation cyclophosphamide-based haploidentical transplantation with myeloablative conditioning and early prophylactic granulocyte colony-stimulating factor–mobilized donor lymphocyte infusions. *Biol Blood Marrow Transplant*. 2016;22(10):1867–73. <https://doi.org/10.1016/j.bbmt.2016.07.016>
18. Kirkham AM, Bailey AJM, Masurekar A, Shorr R, Bredeson C, Sabloff M, Allan DS. Can GCSF-stimulated donor lymphocyte infusions improve outcomes for relapsed disease following allogeneic hematopoietic cell transplantation? A systematic review and meta-analysis. *Leuk Lymphoma*. 2022;63(14):3276–87. <https://doi.org/10.1080/10428194.2022.2118530>
19. Patriarca F, Sperotto A, Lorentino F, Oldani E, Mammoliti S, Isola M, Picardi A, Arcese W, Saporiti G, Sorasio R, Mordini N, Cavattoni I, Musso M, Borghero C, Micò C, Fanin R, Bruno B, Ciceri F, Bonifazi F. Donor lymphocyte infusions after allogeneic stem cell transplantation in acute leukemia: a survey from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). *Front Oncol*. 2020;10:572918. <https://doi.org/10.3389/fonc.2020.572918>
20. Schmid C, Labopin M, Schaap N, Veelken H, Schleuning M, Stadler M, Finke J, Hurst E, Baron F, Ringden O, Bug G, Blaise D, Tischer J, Bloor A, Esteve J, Giebel S, Savani B, Gorin NC, Ciceri F, Mohty M, Nagler A; EBMT Acute Leukaemia Working Party. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. *Br J Haematol*. 2019;184(5):782–7. <https://doi.org/10.1111/bjh.15691>
21. Maurer K, Antin JH. The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy. *Front Immunol*. 2024;15:1328858. <https://doi.org/10.3389/fimmu.2024.1328858>
22. Booth N, Mirea L, Huschart E, Miller H, Salzberg D, Campbell C, Beebe K, Schwalbach C, Adams RH, Ngwube A. Efficacy of azacitidine and prophylactic donor lymphocyte infusion after HCT in pediatric patients with acute myelogenous leukemia: a retrospective pre-post study. *Transplant Cell Ther*. 2023;29(5):330.e1–e7. <https://doi.org/10.1016/j.jtct.2023.02.009>
23. Huschart E, Miller H, Salzberg D, Campbell C, Beebe K, Schwalbach C, Magee K, Adams RH, Ngwube A. Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia. *Pediatr Hematol Oncol*. 2021;38(2):154–60. <https://doi.org/10.1080/08880018.2020.1829220>
24. Suryaprakash S, Sun Y, Tang L, Keerthi D, Qudeimat A, Talleur AC, Mamcarz E, Srinivasan A, Madden R, Epperly R, Naik S, Gottschalk S, Triplett BM, Sharma A. Risk-adapted donor lymphocyte infusion after hematopoietic cell transplant in pediatric and young adult patients is associated with low risk of graft versus host disease. *Transplant Cell Ther*. 2024;30(2 Suppl.):S401. <https://doi.org/10.1016/j.jtct.2023.12.564>

25. Tavares R, Pelegrina P. Prevention and management of relapse of acute leukemia and myelodysplastic syndrome after allogeneic hematopoietic cell transplantation in pediatric patients. *J Bone Marrow Transpl Cell Ther.* 2021;2(4):131. <https://doi.org/10.46765/2675-374X.2021v2n4p131>
26. Bowman S, Stanek J, Bajwa R, Polishchuk V, Abu-Arja R, Rangarajan HG. CD34 stem cell boost in pediatric allogeneic stem cell transplant recipients: a case series and review of literature. *Clin Hematol Int.* 2023;5(2–3): 155–64. <https://doi.org/10.1007/s44228-023-00042-w>
27. Gaffet M, Wiedemann A, Dalle JH, Bilger K, Forcade E, Robin M, Cornillon J, Labussière-Wallet H, Ceballos P, Bulabois CE, Loschi M, Orvain C, Rubio MT, Neven B, Pagliuca S, Pochon C. Efficacy of haematopoietic stem cell boost as a rescue for poor graft function after haematopoietic stem cell transplantation: A multicentre retrospective study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). *Br J Haematol.* 2023;201(6):1153–8. <https://doi.org/10.1111/bjh.18744>
28. Chandra S, Bleesing JJ, Jordan MB, Grimley MS, Khandelwal P, Davies SM, Edwards S, Leemhuis T, Marsh RA. Post-transplant CD34+ selected stem cell “boost” for mixed chimerism after reduced-intensity conditioning hematopoietic stem cell transplantation in children and young adults with primary immune deficiencies. *Biol Blood Marrow Transplant.* 2018;24(7):1527–9. <https://doi.org/10.1016/j.bbmt.2018.03.013>
29. Mainardi C, Ebinger M, Enkel S, Feuchtinger T, Teltschik HM, Eyrich M, Schumm M, Rabsteyn A, Schlegel P, Seitz C, Schwarze CP, Müller I, Greil J, Bader P, Schlegel PG, Martin D, Holzer U, Döring M, Handgretinger R, Lang P. CD34+ selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. *Br J Haematol.* 2018;180(1):90–9. <https://doi.org/10.1111/bjh.15012>
30. Shahzad M, Siddiqui RS, Anwar I, Chaudhary SG, Ali T, Naseem M, Ahmed TF, Ahmed Z, Khurana S, Ahmed N, Balusu R, Singh AK, Hematti P, Callander NS, Abhyankar SH, McGuirk JP, Mushtaq MU. Outcomes with CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. *Transplant Cell Ther.* 2021;27(10):877.e1–e8. <https://doi.org/10.1016/j.jtct.2021.07.012>
31. Nampoothiri RV, Ho L, McEwan C, Pasic I, Lam W, Law AD, Michelis FV, Thyagu S, Kim DDH, Gerbitz A, Viswabandya A, Lipton JH, Mattsson J, Kumar R. Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2021;56(10):2471–6. <https://doi.org/10.1038/s41409-021-01362-2>
32. Ghobadi A, Fiala MA, Ramsingh G, Gao F, Abboud CN, Stockerl-Goldstein K, Uy GL, Grossman BJ, Westervelt P, DiPersio JF. Fresh or cryopreserved CD34+-selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function following allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant.* 2017;23(7):1072–7. <https://doi.org/10.1016/j.bbmt.2017.03.019>
33. Larocca A, Piaggio G, Podestà M, Pitto A, Bruno B, Di Grazia C, Gualandi F, Occhini D, Raiola AM, Dominietto A, Bregante S, Lamparelli T, Tedone E, Oneto R, Frassoni F, Van Lint MT, Pogliani E, Bacigalupo A. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. *Haematologica.* 2006;91(7):935–40.
34. Shapiro RM, Kim HT, Dulery R, Liney D, Garrity HM, Panaro K, Au C, Gervais C, Little JS, Ho VT, Cutler CS, Koreth J, Goptu M, Antin JH, Kelkar AH, Romee R, Wu CJ, Ritz J, Soiffer RJ, Nikiforow S. Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival. *Blood Adv.* 2024;8(17):4729–37. <https://doi.org/10.1182/bloodadvances.2023012418>
35. Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, Ahmed N, Hashmi H. Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy. *Transplant Cell Ther.* 2023;29(9):567–71. <https://doi.org/10.1016/j.jtct.2023.05.012>

36. De Santis GC, de Macedo LD, Orellana MD, Innocentini LMAR, Ferrari TC, Ricz HMA, Caruso SR, Fernandes TR, Covas DT. Mesenchymal stromal cells administration for osteonecrosis of the jaw caused by bisphosphonate: report of two cases. *Acta Oncol.* 2020;59(7):789–92. <https://doi.org/10.1080/0284186x.2020.1730004>
37. Nachmias B, Zimran E, Avni B. Mesenchymal stroma/stem cells: Haematologists' friend or foe? *Br J Haematol.* 2022;199(2):175–89. <https://doi.org/10.1111/bjh.18292>
38. Xu G, Zhang L, Ren G, Yuan Z, Zhang Y, Zhao RC, Shi Y. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. *Cell Res.* 2007;17(3):240–8. <https://doi.org/10.1038/cr.2007.4>
39. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2012;18(8):1150–63. <https://doi.org/10.1016/j.bbmt.2012.04.005>
40. Donadel CD, Pires BG, André NC, Costa TCM, Orellana MD, Caruso SR, Seber A, Ginani VC, Gomes AA, Novis Y, Barros GMN, Vilella NC, Martinho GH, Vieira AK, Kondo AT, Hamerschlak N, Filho JS, Xavier EM, Fernandes JF, Rocha V, Covas DT, Calado RT, Guerino-Cunha RL, De Santis GC. Umbilical cord mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease. *Pharmaceuticals.* 2023;16(4):512. <https://doi.org/10.3390/ph16040512>
41. Dotoli GM, De Santis GC, Orellana MD, de Lima Prata K, Caruso SR, Fernandes TR, Rensi Colturato VA, Kondo AT, Hamerschlak N, Simões BP, Covas DT. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2017;52(6):859–62. <https://doi.org/10.1038/bmt.2017.35>
42. Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, Nemecek E, Neudorf S, Prasad V, Prockop S, Quigg T, Satwani P, Cheng A, Burke E, Hayes J, Skerrett D; MSB-GVHD001/002 Study Group. A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. *Biol Blood Marrow Transplant.* 2020;26(5):845–54. <https://doi.org/10.1016/j.bbmt.2020.01.018>
43. Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, Giebel S, Greinix H, Hazenberg MD, Kröger N, Mielke S, Mohty M, Nagler A, Passweg J, Patriarca F, Ruutu T, Schoemans H, Solano C, Vrhovac R, Wolff D, Zeiser R, Sureda A, Peric Z. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. *Lancet Haematol.* 2024;11(2):e147–59. [https://doi.org/10.1016/s2352-3026\(23\)00342-3](https://doi.org/10.1016/s2352-3026(23)00342-3)